Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijrobp.2022.01.032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.
Therap Adv Gastroenterol
December 2024
Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Giustiniani, 2, Padua 35128, Italy.
Crohn's disease (CD) is a chronic, complex inflammatory disorder of the gastrointestinal tract that presents significant therapeutic challenges. Despite the availability of a wide range of treatments, many patients experience primary non-response, secondary loss of response, or adverse events, limiting the overall effectiveness of current therapies. Clinical trials often report response rates below 60%, partly due to stringent inclusion criteria.
View Article and Find Full Text PDFRepigmentation in non-segmental vitiligo using the Janus kinase inhibitor upadacitinib, a retrospective case series.
Arch Dermatol Res
December 2024
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, No.12 Jiangwangmiao, Xuanwu District, Nanjing, 210042, Jiangsu, China.
Vitiligo is the most frequently diagnosed depigmentation disease, affecting nearly 0.5-2% of individuals worldwide. This disorder is characterized by melanocyte loss, which results in skin and hair depigmentation.
View Article and Find Full Text PDFThe Janus Face of Person-Centred Care.
Int J Geriatr Psychiatry
December 2024
Marie Curie Palliative Care Research Department, Division of Psychiatry, University College London, London, UK.
Janus Wettable Mask with Integrated Ratiometric Fluorescent Probe for Comfortable Exhaled HS Gas Sensing.
ACS Sens
December 2024
Synthetic Biology Research Center, Institute for Advanced Study, Shenzhen University, Shenzhen 518060, China.
The exhaled HS gas is considered a promising noninvasive, rapid biomarker for diagnosing oral health and respiratory diseases. However, there is an urgent need in the healthcare industry for a sensitive, accurate, low-cost, and comfortable wearable breath sensor for HS detection. Herein, a Janus wettable mask was developed by integrating the ratiometric fluorescent probes and asymmetric wettable fabric into the interior of the mask, for the comfortable and visual detection of HS.
View Article and Find Full Text PDFUpadacitinib is associated with clinical response and steroid-free remission for children and adolescents with inflammatory bowel disease.
J Pediatr Gastroenterol Nutr
November 2024
Division of Gastroenterology, Hepatology & Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
Objective: Upadacitinib, an oral Janus kinase inhibitor (JAKi), is approved for inflammatory bowel disease (IBD) in adults. As on-label use will face significant delay in pediatrics, a real-world understanding of safety and efficacy in children is critical.
Methods: This is a single-center retrospective cohort of pediatric subjects (ages 9-20 years) with a diagnosis of IBD initiated on upadacitinib.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!